Should a low‑dose whole‑body CT skeletal survey be obtained in a patient with an IgG paraprotein and immune paresis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, obtain a low-dose whole-body CT skeletal survey in this patient with IgG paraprotein and immune paresis.

A patient presenting with an IgG paraprotein and immune paresis requires skeletal imaging to exclude multiple myeloma, and low-dose whole-body CT is now the preferred modality over conventional skeletal radiography. 1, 2

Rationale for Imaging

The presence of immune paresis (suppression of uninvolved immunoglobulins) alongside a paraprotein significantly elevates concern for multiple myeloma rather than benign MGUS. This combination warrants complete diagnostic workup including:

  • Bone marrow examination
  • Skeletal imaging to detect osteolytic lesions (myeloma-defining events)
  • Laboratory assessment including serum free light chains, β2-microglobulin, and LDH

Why CT Over Conventional Radiography

Low-dose whole-body CT has replaced conventional skeletal surveys as the first-line imaging modality for several compelling reasons 2:

  • Superior sensitivity: CT detects significantly more lytic lesions than plain radiographs, particularly in the spine and ribs
  • Patient comfort: Single acquisition versus multiple radiographic views
  • Faster acquisition: Completed in minutes rather than the prolonged positioning required for skeletal survey
  • Lower radiation: Modern protocols achieve effective doses of 1.5-2.6 mSv 3, comparable to or less than conventional skeletal surveys 4
  • Better assessment of fracture risk: Superior visualization of cortical bone destruction and soft tissue involvement

The 2014 IMWG criteria specifically incorporated whole-body CT as an acceptable alternative to skeletal survey 2. More recent evidence from 2018 IMWG Bone Working Group recommendations provides standardized protocols for CT acquisition and interpretation 2.

Clinical Context Matters

While the 2014 European Myeloma Network guidelines suggest that imaging may not be routinely required for IgG M-protein ≤15 g/L without bone pain 1, the presence of immune paresis changes this calculus entirely. Immune paresis indicates more advanced disease biology and substantially increases the probability of finding:

  • ≥10% clonal plasma cells on bone marrow biopsy
  • Osteolytic lesions on imaging
  • Other myeloma-defining events

The Italian study cited in the guidelines showed very low probability (1.7-2%) of bone lesions in asymptomatic patients with low IgG levels 1, but those data apply to patients without immune paresis.

What to Look For on CT

The radiologist should specifically assess for 2:

  • Osteolytic lesions: Any size, but particularly ≥5 mm
  • Cortical destruction: Indicates high fracture risk
  • Soft tissue components: Paraskeletal or extramedullary disease
  • Pathologic fractures: Especially in weight-bearing bones
  • Diffuse osteopenia: May indicate diffuse marrow involvement

Additional Imaging Considerations

If the whole-body CT is negative for osteolytic lesions but clinical suspicion remains high (particularly if bone marrow shows ≥10% plasma cells), consider adding whole-body MRI 5, 1. MRI can detect:

  • Focal marrow lesions (>1 focal lesion ≥5 mm is a myeloma-defining event)
  • Diffuse marrow infiltration
  • Bone marrow involvement before cortical bone destruction occurs

However, start with CT as the initial imaging modality given its widespread availability, standardized protocols, and ability to detect the most clinically relevant finding: osteolytic bone destruction requiring treatment.

Common Pitfalls to Avoid

  • Don't delay imaging waiting for symptoms: Bone pain is a late finding; asymptomatic lytic lesions are common
  • Don't use standard-dose CT protocols: Low-dose protocols (effective dose ~1.5-2.6 mSv) are adequate and validated 3
  • Don't rely on bone scan: Nuclear medicine bone scans are insensitive for myeloma (lytic lesions don't show increased uptake)
  • Don't skip imaging based solely on M-protein level: Immune paresis indicates higher-risk disease regardless of paraprotein quantity

The combination of IgG paraprotein with immune paresis mandates complete staging evaluation, and low-dose whole-body CT represents the current standard of care for skeletal assessment in this clinical scenario.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.